{"id":35166,"date":"2023-06-12T12:00:00","date_gmt":"2023-06-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/"},"modified":"2023-06-12T12:00:00","modified_gmt":"2023-06-12T12:00:00","slug":"mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/","title":{"rendered":"Mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--2212 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Les biom\u00e9dicaments dans la rhinosinusite chronique avec polypose nasale<\/h2>\n<p><em><strong>Co-auteurs :<\/strong> Pr Wytske Fokkens, Dr An-Sofie Visken, Pr Vibeke Backer, Dr Diego Conti, Mme Elizabeth Van Staeyen, Pr Eugenio de Corso, Pr Philippe Gevaert, Pr Glenis Scadding, Pr Martin Wagemann, Pr Manuel Bernal-Sprekelsen, Dr Adam Chaker, Pr Claire Hopkins, Pr Enrico Heffler, Pr Joseph K. Han, Pr Joaquim Mullol, Pr Peter Hellings, Pr Anju Peters, Pr Brent Senior <\/em><\/p>\n<p>La rhinosinusite chronique s\u00e9v\u00e8re avec polypose nasale (RSCaPN) est une maladie d\u00e9bilitante ayant un impact significatif sur la qualit\u00e9 de vie (QdV). Elle se caract\u00e9rise g\u00e9n\u00e9ralement par une r\u00e9action inflammatoire de type 2 et des comorbidit\u00e9s telles que l\u2019asthme, les allergies et la maladie respiratoire aggrav\u00e9e par les AINS (MRAA). <\/p>\n<p>L\u2019EUFOREA pr\u00e9sente la nouvelle mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la rhinosinusite chronique avec polypose nasale 2023, abordant les directives pratiques pour les patients sous traitement biologique. Dans cet article r\u00e9cemment publi\u00e9, les crit\u00e8res de s\u00e9lection des patients susceptibles de b\u00e9n\u00e9ficier des biom\u00e9dicaments ont \u00e9t\u00e9 mis \u00e0 jour. Des directives sont propos\u00e9es concernant le suivi des effets du m\u00e9dicament permettant d\u2019identifier les r\u00e9pondeurs au traitement et, par la suite, de d\u00e9cider de la poursuite, du changement ou de l\u2019arr\u00eat d\u2019un biom\u00e9dicament.  <\/p>\n<p><span class=\"button-ckeditor button-ckeditor--blue\"><a href=\"https:\/\/www.rhinologyjournal.com\/Abstract.php?id=3069\" target=\"_blank\" rel=\"noopener\"><strong>Lire l\u2019article complet ici<\/strong><\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph image paragraph-id--2213 paragraph--type--image paragraph--view-mode--default clearfix\">\n<div class=\"inner--wide\">\n<h2 class=\"image__title paragraph__title\">Figure 1 : Ajustements des crit\u00e8res EPOS\/EUFOREA. Le seul changement est la r\u00e9duction des \u00e9osinophiles sanguins \u00e0 150 cellules\/\u00b5l <\/h2>\n<div class=\"image__content\"><img decoding=\"async\" src=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EPOS2020-and-EPOSEUFOREA2023-Criteria-.png\"><\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph image paragraph-id--2214 paragraph--type--image paragraph--view-mode--default clearfix\">\n<div class=\"inner--wide\">\n<h2 class=\"image__title paragraph__title\">Figure 2 : Ajustements des crit\u00e8res de r\u00e9ponse EPOS\/EUFOREA<\/h2>\n<div class=\"image__content\"><img decoding=\"async\" src=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Adjustments-in-EPOSEUFOREA-response-criteria-.png\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Les biom\u00e9dicaments dans la rhinosinusite chronique avec polypose nasale Co-auteurs : Pr Wytske Fokkens, Dr An-Sofie Visken, Pr Vibeke Backer, Dr Diego Conti, Mme Elizabeth Van Staeyen, Pr Eugenio de Corso, Pr Philippe Gevaert, Pr Glenis Scadding, Pr Martin Wagemann, Pr Manuel Bernal-Sprekelsen, Dr Adam Chaker, Pr Claire Hopkins, Pr Enrico Heffler, Pr Joseph K. Han, Pr Joaquim Mullol, Pr Peter Hellings, Pr Anju Peters, Pr Brent Senior La rhinosinusite chronique s\u00e9v\u00e8re avec polypose nasale (RSCaPN) est une maladie d\u00e9bilitante ayant un impact significatif sur la qualit\u00e9 de vie (QdV). Elle se caract\u00e9rise g\u00e9n\u00e9ralement par une r\u00e9action inflammatoire de type 2 et des comorbidit\u00e9s telles que l\u2019asthme, les allergies et la maladie respiratoire aggrav\u00e9e par les AINS (MRAA). L\u2019EUFOREA pr\u00e9sente la nouvelle mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la rhinosinusite chronique avec polypose nasale 2023, abordant les directives pratiques pour les patients sous traitement biologique. Dans cet article r\u00e9cemment publi\u00e9, les crit\u00e8res de s\u00e9lection des patients susceptibles de b\u00e9n\u00e9ficier des biom\u00e9dicaments ont \u00e9t\u00e9 mis \u00e0 jour. Des directives sont propos\u00e9es concernant le suivi des effets du m\u00e9dicament permettant d\u2019identifier les r\u00e9pondeurs au traitement et, par la suite, de d\u00e9cider de la poursuite, du changement ou de l\u2019arr\u00eat d\u2019un biom\u00e9dicament. Lire l\u2019article complet ici Figure 1 : Ajustements des crit\u00e8res EPOS\/EUFOREA. Le seul changement est la r\u00e9duction des \u00e9osinophiles sanguins \u00e0 150 cellules\/\u00b5l Figure 2 : Ajustements des crit\u00e8res de r\u00e9ponse EPOS\/EUFOREA<\/p>\n","protected":false},"author":1,"featured_media":35173,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[266],"tags":[172,174,194,195,224,256,297],"class_list":["post-35166","news","type-news","status-publish","has-post-thumbnail","hentry","category-publications","tag-asthme","tag-crswnp","tag-rhinosinusite-chronique-rsc","tag-maladies-respiratoires-chroniques-mrc","tag-polypes-nasaux-np","tag-inflammation-de-type-2","tag-epos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023 - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023\" \/>\n<meta property=\"og:description\" content=\"Les biom\u00e9dicaments dans la rhinosinusite chronique avec polypose nasale Co-auteurs : Pr Wytske Fokkens, Dr An-Sofie Visken, Pr Vibeke Backer, Dr Diego Conti, Mme Elizabeth Van Staeyen, Pr Eugenio de Corso, Pr Philippe Gevaert, Pr Glenis Scadding, Pr Martin Wagemann, Pr Manuel Bernal-Sprekelsen, Dr Adam Chaker, Pr Claire Hopkins, Pr Enrico Heffler, Pr Joseph K. Han, Pr Joaquim Mullol, Pr Peter Hellings, Pr Anju Peters, Pr Brent Senior La rhinosinusite chronique s\u00e9v\u00e8re avec polypose nasale (RSCaPN) est une maladie d\u00e9bilitante ayant un impact significatif sur la qualit\u00e9 de vie (QdV). Elle se caract\u00e9rise g\u00e9n\u00e9ralement par une r\u00e9action inflammatoire de type 2 et des comorbidit\u00e9s telles que l\u2019asthme, les allergies et la maladie respiratoire aggrav\u00e9e par les AINS (MRAA). L\u2019EUFOREA pr\u00e9sente la nouvelle mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la rhinosinusite chronique avec polypose nasale 2023, abordant les directives pratiques pour les patients sous traitement biologique. Dans cet article r\u00e9cemment publi\u00e9, les crit\u00e8res de s\u00e9lection des patients susceptibles de b\u00e9n\u00e9ficier des biom\u00e9dicaments ont \u00e9t\u00e9 mis \u00e0 jour. Des directives sont propos\u00e9es concernant le suivi des effets du m\u00e9dicament permettant d\u2019identifier les r\u00e9pondeurs au traitement et, par la suite, de d\u00e9cider de la poursuite, du changement ou de l\u2019arr\u00eat d\u2019un biom\u00e9dicament. Lire l\u2019article complet ici Figure 1 : Ajustements des crit\u00e8res EPOS\/EUFOREA. Le seul changement est la r\u00e9duction des \u00e9osinophiles sanguins \u00e0 150 cellules\/\u00b5l Figure 2 : Ajustements des crit\u00e8res de r\u00e9ponse EPOS\/EUFOREA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EPOS2020-and-EPOSEUFOREA2023-Criteria-.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\\\/\",\"name\":\"Mise \u00e0 jour EPOS\\\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023 - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EPOS20and20EUFOREA20Update20on20indication20and20evaluation20of20Biologics20in20Chronic20Rhinosinusitis20with20Nasal20Polyps202023_0.png\",\"datePublished\":\"2023-06-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/news\\\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EPOS20and20EUFOREA20Update20on20indication20and20evaluation20of20Biologics20in20Chronic20Rhinosinusitis20with20Nasal20Polyps202023_0.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EPOS20and20EUFOREA20Update20on20indication20and20evaluation20of20Biologics20in20Chronic20Rhinosinusitis20with20Nasal20Polyps202023_0.png\",\"width\":1748,\"height\":1015},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Mise \u00e0 jour EPOS\\\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023 - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/","og_locale":"fr_FR","og_type":"article","og_title":"Mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023","og_description":"Les biom\u00e9dicaments dans la rhinosinusite chronique avec polypose nasale Co-auteurs : Pr Wytske Fokkens, Dr An-Sofie Visken, Pr Vibeke Backer, Dr Diego Conti, Mme Elizabeth Van Staeyen, Pr Eugenio de Corso, Pr Philippe Gevaert, Pr Glenis Scadding, Pr Martin Wagemann, Pr Manuel Bernal-Sprekelsen, Dr Adam Chaker, Pr Claire Hopkins, Pr Enrico Heffler, Pr Joseph K. Han, Pr Joaquim Mullol, Pr Peter Hellings, Pr Anju Peters, Pr Brent Senior La rhinosinusite chronique s\u00e9v\u00e8re avec polypose nasale (RSCaPN) est une maladie d\u00e9bilitante ayant un impact significatif sur la qualit\u00e9 de vie (QdV). Elle se caract\u00e9rise g\u00e9n\u00e9ralement par une r\u00e9action inflammatoire de type 2 et des comorbidit\u00e9s telles que l\u2019asthme, les allergies et la maladie respiratoire aggrav\u00e9e par les AINS (MRAA). L\u2019EUFOREA pr\u00e9sente la nouvelle mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la rhinosinusite chronique avec polypose nasale 2023, abordant les directives pratiques pour les patients sous traitement biologique. Dans cet article r\u00e9cemment publi\u00e9, les crit\u00e8res de s\u00e9lection des patients susceptibles de b\u00e9n\u00e9ficier des biom\u00e9dicaments ont \u00e9t\u00e9 mis \u00e0 jour. Des directives sont propos\u00e9es concernant le suivi des effets du m\u00e9dicament permettant d\u2019identifier les r\u00e9pondeurs au traitement et, par la suite, de d\u00e9cider de la poursuite, du changement ou de l\u2019arr\u00eat d\u2019un biom\u00e9dicament. Lire l\u2019article complet ici Figure 1 : Ajustements des crit\u00e8res EPOS\/EUFOREA. Le seul changement est la r\u00e9duction des \u00e9osinophiles sanguins \u00e0 150 cellules\/\u00b5l Figure 2 : Ajustements des crit\u00e8res de r\u00e9ponse EPOS\/EUFOREA","og_url":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","og_image":[{"url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EPOS2020-and-EPOSEUFOREA2023-Criteria-.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/","url":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/","name":"Mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023 - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EPOS20and20EUFOREA20Update20on20indication20and20evaluation20of20Biologics20in20Chronic20Rhinosinusitis20with20Nasal20Polyps202023_0.png","datePublished":"2023-06-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EPOS20and20EUFOREA20Update20on20indication20and20evaluation20of20Biologics20in20Chronic20Rhinosinusitis20with20Nasal20Polyps202023_0.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EPOS20and20EUFOREA20Update20on20indication20and20evaluation20of20Biologics20in20Chronic20Rhinosinusitis20with20Nasal20Polyps202023_0.png","width":1748,"height":1015},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/news\/mise-a-jour-epos-euforea-sur-lindication-et-levaluation-des-biomedicaments-dans-la-rscapn-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"Mise \u00e0 jour EPOS\/EUFOREA sur l\u2019indication et l\u2019\u00e9valuation des biom\u00e9dicaments dans la RSCaPN 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/35166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=35166"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/35166\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/35173"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=35166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=35166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=35166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}